The National Blood Clot Alliance (NBCA) is pleased to announce a new corporate partnership, as Inari Medical joins NBCA’s Corporate Roundtable this month as a Silver Sponsor in support of NBCA’s mission and the clotting disorders community.
NBCA’s Corporate Roundtable, originally formed in 2015, is a collaborative effort focused on the development of strong and lasting partnerships with the corporations that provide products and services that contribute to the prevention, diagnosis, and treatment of blood clots.
Inari Medical Inc. is a commercial-stage medical device company that recently introduced venous designed mechanical thrombectomy devices for the removal of dangerous blood clots in the veins. These devices are nonsurgical treatment options for deep vein thrombosis (DVT) and pulmonary embolism (PE) that do not involve the use of thrombolytic or clot-dissolving therapies.
NBCA is grateful for the partnership with and support from Inari Medical, and looks forward to a long-standing collaborative relationship in support of the needs of people affected by life-threatening blood clots.
About Inari Medical
Inari is focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs.
The National Blood Clot Alliance (NBCA) is a 501(c)(3), non-profit, voluntary health organization dedicated to advancing the prevention, early diagnosis, and successful treatment of life-threatening blood clots, such as deep vein thrombosis, pulmonary embolism, and clot-provoked stroke. NBCA works on behalf of people who may be susceptible to blood clots, including, but not limited to, people with clotting disorders, atrial fibrillation, cancer, traumatic injury, and risks related to surgery, lengthy immobility, childbirth, and birth control. NBCA accomplishes its mission through programs that build public awareness, educate patients and healthcare professionals, and promote supportive public and private sector policy.